Inside the Glow Peptide Blend

The Glow peptide blend is a compounded combination of three peptides: BPC-157, a 15-amino-acid synthetic peptide; TB-500, a synthetic fragment of the protein thymosin beta-4; and GHK-Cu, a copper-carrying tripeptide found naturally in human plasma. Promise offers Glow as a doctor-prescribed product oriented toward skin renewal and tissue repair, currently by waitlist while its intake form is being built. A licensed provider reviews every request; not everyone qualifies. This article covers what each compound is, what the research does and does not show, and how Glow compares with KLOW, the four-peptide blend that adds KPV.

What is in the Glow peptide blend

The Glow peptide blend contains three compounds in one compounded formulation: BPC-157, TB-500, and GHK-Cu. Each has a distinct identity and a distinct proposed role, which is the entire logic of the blend — one formulation delivering three mechanisms rather than three versions of the same one.

BPC-157 ("Body Protective Compound-157") is a synthetic peptide of 15 amino acids, derived from a partial sequence of a protective protein found in human gastric juice. Its most-studied property is promoting angiogenesis — the formation of new blood vessels.

TB-500 is a synthetic fragment of thymosin beta-4 (Tβ4), a protein present in virtually all human and animal cells. Its active sequence is LKKTETQ — the actin-binding region of the parent protein. TB-500 is not the same molecule as thymosin beta-4, and that distinction matters when reading research: the published wound-healing numbers were generated with thymosin beta-4 itself.

GHK-Cu is the tripeptide glycyl-L-histidyl-L-lysine bound to a copper(II) ion. It occurs naturally in human plasma, where levels decline with age — from roughly 200 ng/mL around age 20 to about 80 ng/mL by age 60, in the historical measurements reported by Loren Pickart's group.

How skin repairs itself

Skin repair proceeds in four overlapping phases: hemostasis, inflammation, proliferation, and remodeling. Understanding those phases explains why a repair-oriented blend combines compounds with different mechanisms rather than three compounds doing the same thing.

In hemostasis, blood vessels constrict and platelets form a clot — a temporary plug that also serves as a provisional matrix for incoming repair cells. Inflammation, typically days 1–3 after an injury, is when damaged cells release signals that attract neutrophils and macrophages; these clear debris, fight pathogens, and release growth factors that cue the next phase. Inflammation is a necessary step, but when it becomes chronic or excessive it can hinder recovery and promote scarring. Proliferation, roughly days 3–14, is the rebuilding phase: fibroblasts migrate into the wound and deposit new extracellular matrix — primarily collagen — while new blood vessels grow in to supply the healing tissue with oxygen and nutrients. Remodeling runs from weeks into months, and can continue for months or even years: haphazardly deposited collagen is reorganized into an aligned structure with greater tensile strength, and scar tissue matures and fades.

Each stage is coordinated by a network of signaling molecules, including peptides and growth factors — which is the biological opening that repair-peptide research tries to work through.

What each compound is studied for

BPC-157 — vascular signaling

BPC-157 is the blend's angiogenesis component. In preclinical work it upregulates VEGF (vascular endothelial growth factor) and acts through the VEGFR2–PI3K–Akt–eNOS signaling axis, driving nitric oxide production, new vessel growth, and vascular stability — a pathway demonstrated in rat ischemic muscle models. A 2025 review by Sikiric and colleagues describes both VEGF-dependent and VEGF-independent routes to nitric oxide. Rodent studies also report enhanced granulation tissue formation, accelerated wound closure, and rapid stimulation of early collagen organization along with expression of the egr-1 gene.

The evidence level matters here. A 2025 systematic review evaluated 36 studies spanning three decades of BPC-157 research in musculoskeletal repair — all in preclinical models. BPC-157's indexed human evidence consists of exactly two pilot studies: a retrospective series in patients with knee pain and a pilot study in interstitial cystitis. A 2024 review in Arthroscopy states plainly that there are no randomized controlled trials of BPC-157 in humans. Its rodent literature in gut and ligament repair is extensive — but it is animal data. For a fuller picture, see our article on BPC-157.

TB-500 — cell migration and collagen architecture

TB-500's mechanism runs through actin, the protein that forms the internal scaffolding cells use to hold their shape and move. Like its parent protein thymosin beta-4, it binds G-actin monomers — a mechanism called actin sequestration — regulating cytoskeletal dynamics and promoting the migration of fibroblasts and keratinocytes toward a wound. Philp and colleagues (2003) showed that the actin-binding site of thymosin beta-4 itself promotes angiogenesis through endothelial cell migration and tubule formation.

The best-known numbers in this area belong to thymosin beta-4, not TB-500. In Malinda et al. (1999), thymosin beta-4 increased wound re-epithelialization by 42% at day 4 and up to 61% at day 7 compared with controls, in rat and mouse full-thickness wound models. Ehrlich and Hazard (2010) found that Tβ4-treated wounds organized their connective tissue better, with reduced myofibroblast formation — wounds matured earlier with minimal scarring and no loss of breaking strength. Goldstein and colleagues (2012) describe thymosin beta-4 as a multi-functional regenerative peptide spanning cell migration, anti-inflammation, and connective tissue organization. Because TB-500 is a fragment carrying the actin-binding sequence, researchers expect overlapping behavior — but the trial-grade attribution belongs to the parent protein. More on the compound in our TB-500 article.

GHK-Cu — copper delivery and collagen gene regulation

GHK-Cu is the blend's skin-chemistry component, and the one with genuinely human cosmetic data. The GHK tripeptide binds copper with very high affinity, and the bound complex delivers that copper into cells more effectively than either the peptide or copper alone. One destination is lysyl oxidase — the copper-dependent enzyme that catalyzes the cross-linking of collagen and elastin, the two proteins that give skin its strength and elasticity.

In fibroblast culture, GHK-Cu stimulates collagen synthesis at picomolar-to-nanomolar concentrations and significantly increases Type I and Type III collagen, along with elastin and glycosaminoglycans; it also promotes endothelial cell proliferation. Gene-expression work by Pickart and Margolina (2018) found GHK-Cu modulates the expression of thousands of human genes, activating regenerative and protective pathways — collagen synthesis, extracellular-matrix remodeling, and antioxidant defense — and it reduces oxidative stress and inflammatory cytokines. In a human comparison reported in the Pickart literature, GHK-Cu applied to facial skin for 12 weeks improved collagen production in 70% of subjects, versus 50% for vitamin C and 40% for retinoic acid. GHK-Cu also remodels: it participates in breaking down old, damaged collagen while stimulating new synthesis. We cover it in depth in What does GHK-Cu do?

If the skin story is what brought you here, GHK-Cu is also available from Promise today as a single-compound prescription — no waitlist involved.

Why combine three peptides in one formulation

The design principle behind Glow is called mechanistic complementarity: choosing compounds that act through distinct receptors and signaling cascades, so a broader biological response is engaged than any single compound could reach. Tissue repair rarely depends on a single mechanism, so single-compound approaches under-describe it.

There is a corollary that cuts the other way: non-redundant pathway engagement. Two peptides acting on the same receptor compete for binding sites and can reduce each other's effect. Blend design, done carefully, avoids stacking compounds that do the same job. In Glow's case the three layers are distinct: BPC-157 works the vascular-signaling side, TB-500 reorganizes the cellular scaffolding that migration and tissue assembly depend on, and GHK-Cu adds a gene-regulatory and enzymatic layer — copper delivery and ECM-gene expression — that neither of the other two provides. Mapped against the wound-healing phases above, the three also span more of the cascade than any one of them alone: vessel supply for the proliferative phase, cell migration and organized collagen deposition, and cross-linking chemistry for remodeling.

Two things keep this grounded. First, no clinical trial of any BPC-157/TB-500/GHK-Cu combination exists — a 2026 review of therapeutic peptides in orthopaedics notes the current lack of clinical trials directly. Complementarity is a design rationale supported by each compound's individual mechanism data, not an outcome demonstrated for the blend. Second, mechanism suggests limits as well as fit: these pathways depend on blood supply, so poorly vascularized tissues are the least plausible setting for them — a limitation, not a promise in reverse.

Blending itself is an established direction in peptide medicine, with combination strategies driving much of the field's growth according to a 2025 review of therapeutic peptides. The clearest human data point for the blend concept comes from a different category: the growth-hormone pair CJC-1295 and Ipamorelin act through two distinct receptor systems (the GHRH receptor via a cAMP-dependent pathway, and GHS-R1a via a calcium-dependent one), and CJC-1295 alone produced 2- to 10-fold dose-dependent increases in plasma growth hormone sustained over six or more days in a human trial. Other compounds studied around skin and cellular aging — such as Epithalon, investigated for activating telomerase, the enzyme that maintains the protective chromosome caps called telomeres — sit outside Glow's repair-focused trio entirely. In preclinical repair studies, effects are measured with concrete markers: inflammatory cytokines such as IL-6 and TNF-α, angiogenesis markers like VEGF and CD31, collagen content via hydroxyproline, fiber organization under polarized light microscopy, and tensile strength testing. That is the standard the combination itself has not yet been held to.

Glow versus KLOW

Glow and KLOW share the same three-peptide core; KLOW adds a fourth compound, KPV. KPV is an ultra-short tripeptide — lysine-proline-valine — cut from alpha-melanocyte-stimulating hormone (α-MSH). It enters cells via PepT1-mediated transport and suppresses NF-κB and MAPK inflammatory signaling, a mechanism established in preclinical intestinal-inflammation work and confirmed in murine models of inflammatory bowel disease. In blend terms, KPV contributes an inflammatory-modulation layer that none of the other three compounds directly targets.

The honest summary: the difference is KPV, and whether that fourth layer is relevant depends on whether calming an inflammatory component is part of what you and your provider are trying to address. Our KLOW article covers the four-compound blend in full.

Compounded, not off the shelf

Glow is prepared as a compounded medication by a licensed U.S. compounding pharmacy working with Promise's prescriber network. Compounding a multi-peptide formulation carries a real analytical burden: each component must maintain its structural integrity, no degradation products may form from inter-peptide reactions, and the stated concentration of every compound must be accurate — verified per component with methods like HPLC purity analysis and mass spectrometry. That burden is exactly why the channel matters. A 2025 narrative review flagged unregulated manufacturing and contamination in the gray-market peptide supply — problems the pharmacy-and-prescription route exists to control for.

On regulatory status: none of the three compounds in Glow has an FDA-approved drug version — not BPC-157, not TB-500, not GHK-Cu — and compounded formulations are not FDA-approved products. In July 2026, FDA's Pharmacy Compounding Advisory Committee voted to recommend both BPC-157 (8–6–1) and TB-500 (8–6–1), along with KPV, for the list of bulk substances that may be used in compounding; the votes are advisory, and rulemaking is still pending. A licensed provider may still prescribe — that decision is between you and your doctor.

Choosing between the blends

If you are weighing Glow against its neighbors, the decision usually reduces to which mechanism layers you and your provider think are relevant — and what is orderable today.

1. Glow (BPC-157 + TB-500 + GHK-Cu) is the three-layer repair core with the skin-chemistry component. It is currently a waitlist product: join at /products/glow and you'll be notified when its intake form goes live.
2. KLOW is the same core plus KPV's inflammatory-modulation layer, and it is available by prescription now.
3. Single compounds — GHK-Cu for the collagen-and-copper story, BPC-157 or TB-500 individually — suit a narrower question, and BPC-157 + TB-500 also exists as the two-compound blend Wolverine — two individually well-studied compounds whose pairing, like Glow's, has no combination trials of its own.

None of these choices is a self-serve decision. The compounds' evidence bases differ (human cosmetic data for topical GHK-Cu, two human pilots for BPC-157, parent-protein data for TB-500, no combination trials at all), individual response varies with injury, baseline health, and adherence, and the call on any prescription rests with the reviewing provider. Bring the question to the consult; that's what the review step is for.

This article is for informational purposes only and is not medical advice.